Danny Liew

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2457553/publications.pdf

Version: 2024-02-01

396 papers 10,639 citations

66234 42 h-index 81 g-index

405 all docs

405 docs citations

405 times ranked 15750 citing authors

#	Article	IF	CITATIONS
1	Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs. JAMA Neurology, 2018, 75, 279.	4.5	910
2	Crohn's disease management after intestinal resection: a randomised trial. Lancet, The, 2015, 385, 1406-1417.	6.3	475
3	Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. BMJ, The, 2021, 375, e068302.	3.0	376
4	Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. Mayo Clinic Proceedings, 2020, 95, 1621-1631.	1.4	342
5	Global Incidence of Frailty and Prefrailty Among Community-Dwelling Older Adults. JAMA Network Open, 2019, 2, e198398.	2.8	289
6	Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure. Archives of Internal Medicine, 2005, 165, 490.	4.3	285
7	Cascade screening based on genetic testing is cost-effective: Evidence for the implementation of models of care for familial hypercholesterolemia. Journal of Clinical Lipidology, 2014, 8, 390-400.	0.6	149
8	The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clinical Therapeutics, 2009, 31, 236-244.	1.1	144
9	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 2013, 136, 3609-3617.	3.7	140
10	Fingolimod after natalizumab and the risk of short-term relapse. Neurology, 2014, 82, 1204-1211.	1.5	138
11	Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Longâ€term Intervention with Pravastatin in Ischaemic Disease (LIPID) study. Australian and New Zealand Journal of Public Health, 2003, 27, 649-653.	0.8	123
12	Recent Patterns of Multimorbidity Among Older Adults in High-Income Countries. Population Health Management, 2019, 22, 127-137.	0.8	120
13	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer. Cancer Discovery, 2019, 9, 354-369.	7.7	104
14	Interventions to reduce medication errors in adult intensive care: a systematic review. British Journal of Clinical Pharmacology, 2012, 74, 411-423.	1.1	103
15	Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. Journal of Hypertension, 2009, 27, 2332-2341.	0.3	102
16	Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients. Journal of Thoracic Oncology, 2013, 8, 461-468.	0.5	102
17	Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions. Neurology, 2014, 83, 2077-2084.	1.5	97
18	N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Research and Therapy, 2012, 14, R143.	1.6	91

#	Article	IF	CITATIONS
19	Characterising risk of in-hospital mortality following cardiac arrest using machine learning: A retrospective international registry study. PLoS Medicine, 2018, 15, e1002709.	3.9	85
20	Cost-Benefit of Minimally Invasive Staging of Non-small Cell Lung Cancer: A Decision Tree Sensitivity Analysis. Journal of Thoracic Oncology, 2010, 5, 1564-1570.	0.5	84
21	Effectiveness of general practice based, practice nurse led telephone coaching on glycaemic control of type 2 diabetes: the Patient Engagement And Coaching for Health (PEACH) pragmatic cluster randomised controlled trial. BMJ, The, 2013, 347, f5272-f5272.	3.0	80
22	Risk of relapse phenotype recurrence in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1511-1522.	1.4	73
23	Pyoderma gangrenosum requiring inpatient management: A report of 26 cases with follow up. Australasian Journal of Dermatology, 2011, 52, 218-221.	0.4	70
24	Subtrochanteric fracture: The effect of cerclage wire on fracture reduction and outcome. Injury, 2015, 46, 1992-1995.	0.7	70
25	Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 890-899.	3.7	64
26	Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 813-819.	1.7	63
27	Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genetics in Medicine, 2019, 21, 1958-1968.	1.1	63
28	A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. International Journal of Cardiology, 2013, 167, 2391-2396.	0.8	62
29	Cardiac fibrosis in the ageing heart: Contributors and mechanisms. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 55-63.	0.9	60
30	Productivity Burden of Hypertension in Australia. Hypertension, 2019, 73, 777-784.	1.3	58
31	Economic burden of obesity in primary total knee arthroplasty. Arthritis Care and Research, 2011, 63, 1375-1381.	1.5	57
32	The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Research and Therapy, 2013, 15, R193.	1.6	57
33	The Productivity Burden of Diabetes at a Population Level. Diabetes Care, 2018, 41, 979-984.	4.3	57
34	Attitudes towards antimicrobial stewardship: results from a large private hospital in Australia. Healthcare Infection, 2014, 19, 89-94.	0.6	51
35	Projected Burden of Osteoarthritis and Rheumatoid Arthritis in Australia: A Populationâ€Level Analysis. Arthritis Care and Research, 2018, 70, 877-883.	1.5	51
36	Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation. Pharmacoeconomics, 2017, 35, 1257-1270.	1.7	49

#	Article	IF	CITATIONS
37	The Efficacy of Technology in Type 1 Diabetes: A Systematic Review, Network Meta-analysis, and Narrative Synthesis. Diabetes Technology and Therapeutics, 2020, 22, 411-421.	2.4	49
38	Excess mortality and hospitalized morbidity in newly treated epilepsy patients. Neurology, 2016, 87, 718-725.	1.5	48
39	Poorer outcomes and greater healthcare costs for hospitalised older people with dementia and delirium: a retrospective cohort study. International Journal of Geriatric Psychiatry, 2017, 32, 539-547.	1.3	48
40	Effect of Comorbidity Assessed by the Charlson Comorbidity Index on the Length of Stay, Costs and Mortality among Older Adults Hospitalised for Acute Stroke. International Journal of Environmental Research and Public Health, 2018, 15, 2532.	1.2	48
41	Systematic review with metaâ€analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Alimentary Pharmacology and Therapeutics, 2018, 48, 780-796.	1.9	48
42	Overview of methods for comparing the efficacies of drugs in the absence of headâ€toâ€head clinical trial data. British Journal of Clinical Pharmacology, 2014, 77, 116-121.	1.1	46
43	Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1426-1435.	1.4	46
44	Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. BMJ: British Medical Journal, 2017, 356, j783.	2.4	46
45	A Systematic Review and Meta-analysis of the Factors Associated With Nonadherence and Discontinuation of Statins Among People Aged ≥65 Years. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 798-805.	1.7	46
46	Cardiorenal syndrome: Multiâ€organ dysfunction involving the heart, kidney and vasculature. British Journal of Pharmacology, 2020, 177, 2906-2922.	2.7	46
47	Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged ≥70. BMJ: British Medical Journal, 2005, 330, 1306.	2.4	45
48	Comparison of Health-Related Quality of Life, Work Status, and Health Care Utilization and Costs According to Hip and Knee Joint Disease Severity: A National Australian Study. Physical Therapy, 2013, 93, 889-899.	1.1	45
49	Rethinking pandemic preparation: Global Health Security Index (GHSI) is predictive of COVID-19 burden, but in the opposite direction. Journal of Infection, 2020, 81, 318-356.	1.7	45
50	Accuracy of national mortality codes in identifying adjudicated cardiovascular deaths. Australian and New Zealand Journal of Public Health, 2011, 35, 466-476.	0.8	44
51	Cost-Effectiveness of Thrombolysis Within 4.5 Hours of Acute Ischemic Stroke. Stroke, 2013, 44, 2269-2274.	1.0	44
52	The costâ€benefit of using soft silicone multilayered foam dressings to prevent sacral and heel pressure ulcers in trauma and critically ill patients: a withinâ€trial analysis of the Border Trial. International Wound Journal, 2015, 12, 344-350.	1.3	44
53	Resting heart rate, temporal changes in resting heart rate, and overall and cause-specific mortality. Heart, 2018, 104, 1076-1085.	1.2	43
54	The Role of Traditional Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 34-40.	1.0	42

#	Article	IF	CITATIONS
55	Current and emerging antiviral treatments for hepatitis <scp>C</scp> infection. British Journal of Clinical Pharmacology, 2013, 75, 931-943.	1.1	42
56	Identification of Urinary Biomarkers for Age-Related Macular Degeneration., 2011, 52, 4639.		40
57	Estimating the lifetime economic burden of stroke according to the age of onset in South Korea: a cost of illness study. BMC Public Health, 2011, 11, 646.	1.2	40
58	Hepatic macrophage activation predicts clinical decompensation in chronic liver disease. Gut, 2013, 62, 1231-1232.	6.1	40
59	The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model. BMJ, The, 2012, 344, e3657-e3657.	3.0	39
60	The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice. Heart Failure Reviews, 2016, 21, 675-697.	1.7	39
61	Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort. Open Heart, 2018, 5, e000782.	0.9	39
62	Impact of scribes on emergency medicine doctors' productivity and patient throughput: multicentre randomised trial. BMJ: British Medical Journal, 2019, 364, l121.	2.4	39
63	The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. PLoS ONE, 2013, 8, e59694.	1.1	38
64	Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. Cardiovascular Research, 2019, 115, 266-276.	1.8	38
65	Effect of Bariatric Surgery on Risk of Complications After Total Knee Arthroplasty. JAMA Network Open, 2022, 5, e226722.	2.8	38
66	The COACH Program Produces Sustained Improvements in Cardiovascular Risk Factors and Adherence to Recommended Medications—Two Years Follow-up. Heart Lung and Circulation, 2009, 18, 388-392.	0.2	37
67	The association between radiographic severity and pre-operative function in patients undergoing primary knee replacement for osteoarthritis. Knee, 2012, 19, 860-865.	0.8	37
68	Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment. Neurology, 2016, 86, 1086-1094.	1.5	37
69	A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005 - 2016. BMC Infectious Diseases, 2019, 19, 274.	1.3	37
70	Controlled clinical trial of a self-management program for people with mental illness in an adult mental health service - the Optimal Health Program (OHP). Australian Health Review, 2012, 36, 1.	0.5	36
71	Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?. Atherosclerosis, 2020, 304, 1-8.	0.4	36
72	Overview of pharmacoeconomic modelling methods. British Journal of Clinical Pharmacology, 2013, 75, 944-950.	1.1	35

#	Article	IF	CITATIONS
73	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. European Journal of Preventive Cardiology, 2021, 28, 975-982.	0.8	35
74	Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: A Health Economic Analysis. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006789.	0.9	34
75	Radial probe EBUS <i>versus</i> CT-guided needle biopsy for evaluation of peripheral pulmonary lesions: an economic analysis. European Respiratory Journal, 2013, 41, 539-547.	3.1	33
76	Echocardiographic monitoring for clozapine cardiac toxicity: lessons from real-world experience. Australasian Psychiatry, 2013, 21, 258-261.	0.4	33
77	Moving From Heart Failure Guidelines to Clinical Practice: Gaps Contributing to Readmissions in Patients With Multiple Comorbidities and Older Age. Clinical Medicine Insights: Cardiology, 2018, 12, 117954681880935.	0.6	33
78	Using technology to support care in gestational diabetes mellitus: Quantitative outcomes of an exploratory randomised control trial of adjunct telemedicine for gestational diabetes mellitus (TeleGDM). Diabetes Research and Clinical Practice, 2018, 142, 276-285.	1.1	33
79	Productivity burden of smoking in Australia: a life table modelling study. Tobacco Control, 2019, 28, 297-304.	1.8	33
80	Skipping Breakfast and the Risk of Cardiovascular Disease and Death: A Systematic Review of Prospective Cohort Studies in Primary Prevention Settings. Journal of Cardiovascular Development and Disease, 2019, 6, 30.	0.8	33
81	Deterioration of Cortical and Trabecular Microstructure Identifies Women With Osteopenia or Normal Bone Mineral Density at Imminent and Longâ€Term Risk for Fragility Fracture: A Prospective Study. Journal of Bone and Mineral Research, 2020, 35, 833-844.	3.1	33
82	Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis. Ecancermedicalscience, 2020, 14, 1047.	0.6	33
83	A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clinical Therapeutics, 2007, 29, 242-252.	1.1	32
84	Pharmacists' Interprofessional Communication About Medications in Specialty Hospital Settings. Health Communication, 2015, 30, 1065-1075.	1.8	32
85	Patterns of statin use and longâ€ŧerm adherence and persistence among older adults with diabetes. Journal of Diabetes, 2018, 10, 699-707.	0.8	32
86	Predictors of firstâ€year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. British Journal of Clinical Pharmacology, 2019, 85, 227-235.	1.1	32
87	The impact of diabetes on productivity in China. Diabetologia, 2019, 62, 1195-1203.	2.9	31
88	The role of dihydrosphingolipids in disease. Cellular and Molecular Life Sciences, 2019, 76, 1107-1134.	2.4	31
89	Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. Journal of Antimicrobial Chemotherapy, 2010, 65, 1052-1061.	1.3	30
90	Validation of two Framingham cardiovascular risk prediction algorithms in an Australian population: the â€~old' versus the â€~new' Framingham equation. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 115-120.	3.1	30

#	Article	IF	CITATIONS
91	Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 17-26.	5.5	30
92	Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis. Diabetes Care, 2020, 43, 1967-1975.	4.3	30
93	Observational studies and their utility for practice. Australian Prescriber, 2018, 41, 82-85.	0.5	30
94	Cardiovascular effects of selective cyclooxygenase-2 inhibitors. Expert Review of Cardiovascular Therapy, 2004, 2, 265-270.	0.6	29
95	Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. Journal of Antimicrobial Chemotherapy, 2011, 66, 1906-1915.	1.3	29
96	Implementing antimicrobial stewardship in the Australian private hospital system: a qualitative study. Australian Health Review, 2015, 39, 315.	0.5	29
97	Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 64-73.	0.6	29
98	Clearing emergency departments and clogging wards: National Emergency Access Target and the law of unintended consequences. EMA - Emergency Medicine Australasia, 2014, 26, 549-555.	0.5	28
99	An economic evaluation of the costs of training a medical scribe to work in Emergency Medicine. Emergency Medicine Journal, 2016, 33, 865-869.	0.4	28
100	Role of immunohistochemistry in the era of genetic testing in <i>MYC</i> -positive aggressive B-cell lymphomas: a study of 209 cases. Journal of Clinical Pathology, 2016, 69, 266-270.	1.0	28
101	Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review. Genetics in Medicine, 2018, 20, 1145-1156.	1.1	28
102	The costs of epilepsy in Australia. Neurology, 2020, 95, e3221-e3231.	1.5	28
103	The Association Between Age of Onset of Type 2 Diabetes and the Long-term Risk of End-Stage Kidney Disease: A National Registry Study. Diabetes Care, 2020, 43, 1788-1795.	4.3	28
104	Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. Pharmacoeconomics, 2020, 38, 1095-1113.	1.7	28
105	Cohort Profile: The Hazelwood Health Study Adult Cohort. International Journal of Epidemiology, 2021, 49, 1777-1778.	0.9	27
106	Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study. Heart, 2013, 99, 1353-1358.	1.2	26
107	Natural Regression of Frailty Among Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis. Gerontologist, The, 2020, 60, e286-e298.	2.3	26
108	Angiotensin converting enzyme genotypes and mortality from COVID-19: An ecological study. Journal of Infection, 2020, 81, 961-965.	1.7	26

#	Article	IF	CITATIONS
109	Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. International Journal of Evidence-Based Healthcare, 2012, 10, 211-221.	0.1	25
110	Diabetes Prevention and Treatment Strategies. Diabetes Care, 2013, 36, 2714-2719.	4.3	25
111	Do statin users adhere to a healthy diet and lifestyle? The Australian Diabetes, Obesity and Lifestyle Study. European Journal of Preventive Cardiology, 2017, 24, 621-627.	0.8	25
112	Burden of cardiovascular risk factors and disease among patients with type 1 diabetes: results of the Australian National Diabetes Audit (ANDA). Cardiovascular Diabetology, 2018, 17, 77.	2.7	25
113	Dr Foster global frailty score: an international retrospective observational study developing and validating a risk prediction model for hospitalised older persons from administrative data sets. BMJ Open, 2019, 9, e026759.	0.8	25
114	Effects of patient-, environment- and medication-related factors on high-alert medication incidents. International Journal for Quality in Health Care, 2014, 26, 308-320.	0.9	24
115	Drugâ€induced hepatotoxicity: incidence of abnormal liver function tests consistent with volatile anaesthetic hepatitis in trauma patients. Liver International, 2014, 34, 576-582.	1.9	24
116	A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. Value in Health, 2016, 19, 1009-1015.	0.1	24
117	A 10-Year Trend in Statin Use Among Older Adults in Australia: an Analysis Using National Pharmacy Claims Data. Cardiovascular Drugs and Therapy, 2018, 32, 265-272.	1.3	24
118	Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. International Journal of Cardiology, 2018, 270, 54-59.	0.8	24
119	Lifestyle Changes in Relation to Initiation of Antihypertensive and Lipid‣owering Medication: A Cohort Study. Journal of the American Heart Association, 2020, 9, e014168.	1.6	24
120	Substitution Monotherapy With Levetiracetam vs Older Antiepileptic Drugs. Archives of Neurology, 2012, 69, 1563.	4.9	23
121	Barriers and enablers affecting patient engagement in managing medications within specialty hospital settings. Health Expectations, 2015, 18, 2787-2798.	1.1	23
122	Caring for people with dementia in hospital: findings from a survey to identify barriers and facilitators to implementing best practice dementia care. International Psychogeriatrics, 2017, 29, 467-474.	0.6	23
123	The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective. International Journal of Cardiology, 2018, 267, 183-187.	0.8	23
124	Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario. American Journal of Hypertension, 2018, 31, 1156-1163.	1.0	23
125	Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. Journal of Antimicrobial Chemotherapy, 2008, 63, 197-208.	1.3	22
126	An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study. Diabetes Research and Clinical Practice, 2014, 106, 247-255.	1.1	22

#	Article	IF	CITATIONS
127	Incidence of fatal snake bite in Australia: A coronial based retrospective study (2000–2016). Toxicon, 2017, 131, 11-15.	0.8	22
128	Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease. Journal of Crohn's and Colitis, 2018, 12, 653-661.	0.6	22
129	Cost of gastroenteritis in Australia: A healthcare perspective. PLoS ONE, 2018, 13, e0195759.	1.1	22
130	Histidineâ€containing dipeptides reduce central obesity and improve glycaemic outcomes: A systematic review and metaâ€analysis of randomized controlled trials. Obesity Reviews, 2020, 21, e12975.	3.1	22
131	Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis. European Heart Journal, 2022, 43, 3243-3254.	1.0	22
132	Nâ€terminal Bâ€type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the SCReening Evaluation of the Evolution of Newâ€Heart Failure Study (SCREENâ€HF). European Journal of Heart Failure, 2013, 15, 573-580.	2.9	21
133	Serologic antibodies in relation to outcome in postoperative Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1195-1203.	1.4	21
134	Threshold body mass index and sex-specific waist circumference for increased risk of heart failure with preserved ejection fraction. European Journal of Preventive Cardiology, 2019, 26, 1594-1602.	0.8	21
135	Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health. Value in Health, 2019, 22, 593-600.	0.1	21
136	Prediction of incident heart failure by serum aminoâ€terminal proâ€Bâ€type natriuretic peptide level in a communityâ€based cohort. European Journal of Heart Failure, 2019, 21, 449-459.	2.9	21
137	The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. European Journal of Preventive Cardiology, 2021, 28, 897-904.	0.8	21
138	Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden. Pharmacoeconomics, 2021, 39, 271-273.	1.7	21
139	Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029. European Journal of Preventive Cardiology, 2022, 29, 1212-1219.	0.8	21
140	Cost-effectiveness of health technologies in adults with type 1 diabetes: a systematic review and narrative synthesis. Systematic Reviews, 2020, 9, 171.	2.5	20
141	Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis. Pharmacoeconomics, 2020, 38, 1007-1020.	1.7	20
142	Blood Pressure Effects of COX-2 Inhibitors. Journal of Cardiovascular Pharmacology, 2006, 47, S43-S48.	0.8	19
143	Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. Journal of Antimicrobial Chemotherapy, 2009, 63, 1276-1285.	1.3	19
144	Clinicians' adherence to international guidelines in the clinical care of adults with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2017, 52, 536-542.	0.6	19

#	Article	IF	Citations
145	Economic evaluation of clinical quality registries: a systematic review. BMJ Open, 2019, 9, e030984.	0.8	19
146	Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. European Journal of Preventive Cardiology, 2019, 26, 858-868.	0.8	19
147	Impact of tobacco use on health and work productivity in Malaysia. Tobacco Control, 2020, 29, 111-117.	1.8	19
148	Costâ€effectiveness and financial risks associated with immune checkpoint inhibitor therapy. British Journal of Clinical Pharmacology, 2020, 86, 1703-1710.	1.1	19
149	Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 812-821.	2.4	19
150	Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers. Genetics in Medicine, 2020, 22, 831-839.	1.1	19
151	Association of Spicy Chilli Food Consumption With Cardiovascular and All-Cause Mortality: A Meta-Analysis of Prospective Cohort Studies. Angiology, 2021, 72, 625-632.	0.8	19
152	Quantifying the excess cost and resource utilisation for patients with complications associated with elective knee arthroscopy: A retrospective cohort study. Knee, 2014, 21, 491-496.	0.8	18
153	Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia. European Journal of Preventive Cardiology, 2015, 22, 344-353.	0.8	18
154	Switching, Discontinuation, and Reinitiation of Statins Among Older Adults. Journal of the American College of Cardiology, 2018, 72, 2675-2677.	1.2	18
155	Educating junior doctors and pharmacists to reduce discharge prescribing of opioids for surgical patients: a cluster randomised controlled trial. Medical Journal of Australia, 2020, 213, 417-423.	0.8	18
156	The impact of diabetes on the productivity and economy of Bangladesh. BMJ Global Health, 2020, 5, e002420.	2.0	18
157	Attenuating PI3K/Akt- mTOR pathway reduces dihydrosphingosine 1 phosphate mediated collagen synthesis and hypertrophy in primary cardiac cells. International Journal of Biochemistry and Cell Biology, 2021, 134, 105952.	1.2	18
158	Real-World Efficiency of Pharmacogenetic Screening for Carbamazepine-Induced Severe Cutaneous Adverse Reactions. PLoS ONE, 2014, 9, e96990.	1.1	18
159	Cost-effectiveness of transcatheter aortic valve implantation compared to surgical aortic valve replacement in the intermediate surgical risk population. International Journal of Cardiology, 2019, 294, 17-22.	0.8	17
160	Prevalence and impact of non-cardiovascular comorbidities among older adults hospitalized for non-ST segment elevation acute coronary syndrome. Cardiovascular Diagnosis and Therapy, 2019, 9, 250-261.	0.7	17
161	Coronary artery calcium scoring in cardiovascular risk assessment of people with family histories of early onset coronary artery disease. Medical Journal of Australia, 2020, 213, 170-177.	0.8	17
162	Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients With Severe Aortic Stenosis. Heart Lung and Circulation, 2021, 30, 547-554.	0.2	17

#	Article	IF	Citations
163	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 31-37.	1.5	16
164	Cost-Effectiveness of 12-Month Treatment With Ticagrelor Compared With Clopidogrel in the Management of Acute Coronary Syndromes. Clinical Therapeutics, 2013, 35, 1110-1117.e9.	1.1	16
165	Performance of the Assessment of Quality of Life Measure in People With Hip and Knee Joint Disease and Implications for Research and Clinical Use. Arthritis Care and Research, 2014, 66, 481-488.	1.5	16
166	Medication communication during handover interactions in specialty practice settings. Journal of Clinical Nursing, 2015, 24, 2859-2870.	1.4	16
167	Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma. Pathology, 2016, 48, 660-665.	0.3	16
168	Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis. European Journal of Preventive Cardiology, 2021, 28, 966-972.	0.8	16
169	Clinical decision support improves quality of care in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2019, 49, 1040-1051.	1.9	16
170	Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma. Journal of Medical Economics, 2019, 22, 531-544.	1.0	15
171	Exogenous dihydrosphingosine 1 phosphate mediates collagen synthesis in cardiac fibroblasts through JAK/STAT signalling and regulation of TIMP1. Cellular Signalling, 2020, 72, 109629.	1.7	15
172	Poor adherence and persistence to sodium glucose coâ€transporter 2 inhibitors in realâ€world settings: Evidence from a systematic review and metaâ€analysis. Diabetes/Metabolism Research and Reviews, 2021, 37, e3350.	1.7	15
173	Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea. Clinical Therapeutics, 2009, 31, 2189-2203.	1.1	14
174	Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: The Korean Individual-Microsimulation Model for Cardiovascular Health Interventions. Clinical Therapeutics, 2009, 31, 2919-2930.	1.1	14
175	Drug Treatment and Cost of Cardiovascular Disease in Australia. Cardiovascular Therapeutics, 2009, 27, 164-172.	1.1	14
176	Can primary care team-based transition to insulin improve outcomes in adults with type 2 diabetes: the stepping up to insulin cluster randomized controlled trial protocol. Implementation Science, 2014, 9, 20.	2.5	14
177	Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open, 2016, 6, e011028.	0.8	14
178	Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective. Medicine (United States), 2016, 95, e3531.	0.4	14
179	Criteria for Identifying Patients With Staphylococcus aureus Bacteremia Who Are at Low Risk of Endocarditis: A Systematic Review. Open Forum Infectious Diseases, 2017, 4, ofx261.	0.4	14
180	Additional structured physical activity does not improve walking in older people (> 60 years) undergoing inpatient rehabilitation: a randomised trial. Journal of Physiotherapy, 2018, 64, 237-244.	0.7	14

#	Article	IF	CITATIONS
181	Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. Scientific Reports, 2019, 9, 3256.	1.6	14
182	A prospective study of the incidence of drugâ€induced liver injury by the modern volatile anaesthetics sevoflurane and desflurane. Alimentary Pharmacology and Therapeutics, 2019, 49, 940-951.	1.9	14
183	Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling. BMJ Open, 2020, 10, e039221.	0.8	14
184	Switching, Persistence and Adherence to Statin Therapy: a Retrospective Cohort Study Using the Australian National Pharmacy Data. Cardiovascular Drugs and Therapy, 2022, 36, 867-877.	1.3	14
185	Long-Term Outcome of Multidisciplinary Versus Standard Gastroenterologist Care for Functional Gastrointestinal Disorders: A Randomized Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 2102-2111.e9.	2.4	14
186	Epidemiological modelling (including economic modelling) and its role in preventive drug therapy. Medical Journal of Australia, 2002, 177, 364-367.	0.8	13
187	Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. Medical Journal of Australia, 2012, 196, 193-197.	0.8	13
188	NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: Results of the SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF). International Journal of Cardiology, 2013, 169, 133-138.	0.8	13
189	Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms. European Journal of Preventive Cardiology, 2014, 21, 384-390.	0.8	13
190	SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF): early detection of chronic heart failure in the workplace. Australian Health Review, 2017, 41, 121.	0.5	13
191	Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 139-154.	0.7	13
192	The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. International Journal of Cardiology, 2019, 285, 1-5.	0.8	13
193	The Frequency of, and Factors Associated with Prolonged Hospitalization: A Multicentre Study in Victoria, Australia. Journal of Clinical Medicine, 2020, 9, 3055.	1.0	13
194	Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis. Journal of Clinical Lipidology, 2020, 14, 772-783.	0.6	13
195	Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes. Acta Diabetologica, 2021, 58, 39-46.	1.2	13
196	First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis. Current Problems in Cardiology, 2022, 47, 100852.	1.1	13
197	The economic impact of sudden cardiac arrest. Resuscitation, 2021, 163, 49-56.	1.3	13
198	Endoscopic Prediction of Crohn's Disease Postoperative Recurrence. Inflammatory Bowel Diseases, 2022, 28, 680-688.	0.9	13

#	Article	IF	CITATIONS
199	Clinical characteristics of people with heart failure in Australian general practice: results from a retrospective cohort study. ESC Heart Failure, 2021, 8, 4497-4505.	1.4	13
200	Aldosterone Receptor Antagonists for Hypertension. Drugs, 2003, 63, 1963-1972.	4.9	12
201	Predicting blood loss and transfusion requirement in patients undergoing surgery for musculoskeletal tumors. Transfusion, 2014, 54, 1469-1477.	0.8	12
202	Using WOMAC Index scores and personal characteristics to estimate Assessment of Quality of Life utility scores in people with hip and knee joint disease. Quality of Life Research, 2014, 23, 2365-2374.	1.5	12
203	Cost Effectiveness of Eplerenone in Patients with Chronic Heart Failure. American Journal of Cardiovascular Drugs, 2014, 14, 209-216.	1.0	12
204	Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents. Vaccine, 2019, 37, 5009-5015.	1.7	12
205	Molecular mechanisms of protein-bound uremic toxin-mediated cardiac, renal and vascular effects: underpinning intracellular targets for cardiorenal syndrome therapy. Toxicology Letters, 2019, 308, 34-49.	0.4	12
206	A Markov costâ€effective analysis of biannual fluoride varnish for preventing dental caries in permanent teeth over a 70â€year time horizon. Health Promotion Journal of Australia, 2020, 31, 177-183.	0.6	12
207	Efficacy of interpersonal psychotherapy for post-traumatic stress disorder: A systematic review and meta-analysis. Journal of Affective Disorders, 2020, 264, 286-294.	2.0	12
208	Impact of limited English proficiency on presentation and clinical outcomes of patients undergoing primary percutaneous coronary intervention. European Heart Journal Quality of Care & Dinical Outcomes, 2020, 6, 254-262.	1.8	12
209	Prescription Medication Use in Older Adults Without Major Cardiovascular Disease Enrolled in the Aspirin in Reducing Events in the Elderly (ASPREE) Clinical Trial. Pharmacotherapy, 2020, 40, 1042-1053.	1.2	12
210	Productivity Burden of Occupational Noise-Induced Hearing Loss in Australia: A Life Table Modelling Study. International Journal of Environmental Research and Public Health, 2020, 17, 4667.	1.2	12
211	A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 515-522.	3.1	11
212	The "cost―of treating to target: cross-sectional analysis of patients with poorly controlled type 2 diabetes in Australian general practice. BMC Family Practice, 2013, 14, 32.	2.9	11
213	Prevalence and Incidence of Statin Use and 3-Year Adherence and Discontinuation Rates Among Older Adults With Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2018, 33, 527-534.	0.9	11
214	Ambiguous medical abbreviation study: challenges and opportunities. Internal Medicine Journal, 2020, 50, 1073-1078.	0.5	11
215	The economic impact of familial hypercholesterolemia on productivity. Journal of Clinical Lipidology, 2020, 14, 799-806.e3.	0.6	11
216	Future burden of vision loss in Australia: Projections from the National Eye Health Survey. Clinical and Experimental Ophthalmology, 2020, 48, 730-738.	1.3	11

#	Article	IF	CITATIONS
217	Carnosine and histidine-containing dipeptides improve dyslipidemia: a systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews, 2020, 78, 939-951.	2.6	11
218	Ageâ€related longitudinal change in cardiac structure and function in adults at increased cardiovascular risk. ESC Heart Failure, 2020, 7, 1344-1361.	1.4	11
219	Burden of disease and productivity impact of Streptococcus suis infection in Thailand. PLoS Neglected Tropical Diseases, 2021, 15, e0008985.	1.3	11
220	Projecting the Incidence of Type 2 Diabetes–Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment. Diabetes Care, 2021, 44, 1515-1523.	4.3	11
221	The Health and Productivity Burden of Depression in South Korea. Applied Health Economics and Health Policy, 2021, 19, 941-951.	1.0	11
222	The impact of coronary heart disease prevention on work productivity: a 10-year analysis. European Journal of Preventive Cardiology, 2021, 28, 418-425.	0.8	11
223	Characteristics of national and major regional percutaneous coronary intervention registries: a structured literature review. EuroIntervention, 2018, 14, 1112-1120.	1.4	11
224	A Model for Predicting the Future Incidence of Coronary Heart Disease Within Percentiles of Coronary Heart Disease Risk. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 31-37.	3.1	10
225	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 41-55.	1.5	10
226	Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?. Journal of Hypertension, 2006, 24, 1979-1984.	0.3	10
227	Economic evaluation of micafungin vs. Liposomal Amphotericin B (LAmB) for the treatment of candidaemia and Invasive Candidiasis (IC). Mycoses, 2013, 56, 532-542.	1.8	10
228	A randomized controlled trial of physical activity with individual goal-setting and volunteer mentors to overcome sedentary lifestyle in older adults at risk of cognitive decline: the INDIGO trial protocol. BMC Geriatrics, 2017, 17, 215.	1,1	10
229	Benefit of targeted, pharmacistâ€led education for junior doctors in reducing prescription writing errors – a controlled trial. Journal of Pharmacy Practice and Research, 2018, 48, 26-35.	0.5	10
230	Risk factor management in a contemporary Australian population at increased cardiovascular disease risk. Internal Medicine Journal, 2018, 48, 688-698.	0.5	10
231	LDLâ€Cholesterol Is the Only Clinically Relevant Biomarker for Atherosclerotic Cardiovascular Disease (ASCVD) Risk. Clinical Pharmacology and Therapeutics, 2018, 104, 235-238.	2.3	10
232	Reinitiation of Statin Therapy After Discontinuation: A Meta-analysis. Mayo Clinic Proceedings, 2018, 93, 666-668.	1.4	10
233	Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study. Advances in Therapy, 2019, 36, 3265-3278.	1.3	10
234	Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand. Pharmacoeconomics, 2019, 37, 1277-1286.	1.7	10

#	Article	IF	Citations
235	First seizure presentations in adults: beyond assessment and treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1039-1045.	0.9	10
236	A populationâ€based analysis of attributable hospitalisation costs of invasive fungal diseases in haematological malignancy patients using data linkage of stateâ€wide registry and costing databases: 2009â€2015. Mycoses, 2020, 63, 162-171.	1.8	10
237	Incidence, Predictors and Clinical Outcomes of Stent Thrombosis Following Percutaneous Coronary Intervention in Contemporary Practice. Heart Lung and Circulation, 2020, 29, 1433-1439.	0.2	10
238	The Health and Productivity Burden of Migraines in Australia. Headache, 2020, 60, 2291-2303.	1.8	10
239	Incidence and Predictors of Unplanned Hospital Readmission after Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2020, 9, 3242.	1.0	10
240	Do family meetings for hospitalised palliative care patients improve outcomes and reduce health care costs? A cluster randomised trial. Palliative Medicine, 2021, 35, 188-199.	1.3	10
241	Are Lifestyle Interventions to Reduce Excessive Gestational Weight Gain Cost Effective? A Systematic Review. Current Diabetes Reports, 2020, 20, 6.	1.7	10
242	Attainment of Low-Density Lipoprotein Cholesterol Goals in Statin Treated Patients: Real-World Evidence From Australia. Current Problems in Cardiology, 2022, 47, 101068.	1.1	10
243	New developments in the pharmacological treatment of chronic heart failure. Expert Opinion on Investigational Drugs, 2003, 12, 751-757.	1.9	9
244	Do Patients Who Take Part in Stroke Research Differ from Non-Participants? Implications for Generalizability of Results. Cerebrovascular Diseases, 2013, 35, 483-491.	0.8	9
245	Examination of the relationship between disease activity and patientâ€reported outcome measures in an inflammatory bowel disease cohort. Internal Medicine Journal, 2018, 48, 1234-1241.	0.5	9
246	What risk of endocarditis is low enough to justify the omission of transoesophageal echocardiography in Staphylococcus aureus bacteraemia? A narrative review. Clinical Microbiology and Infection, 2018, 24, 1251-1256.	2.8	9
247	Benefit of Echocardiography in Patients With Staphylococcus aureus Bacteremia at Low Risk of Endocarditis. Open Forum Infectious Diseases, 2018, 5, ofy303.	0.4	9
248	Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective. Heart Lung and Circulation, 2020, 29, 1310-1317.	0.2	9
249	Prevalence, Outcomes and Cost Implications of Patients Undergoing Same Day Discharge After Elective Percutaneous Coronary Intervention in Australia. Heart Lung and Circulation, 2020, 29, e185-e193.	0.2	9
250	Cost Burden and Cost-Effective Analysis of the Nationwide Implementation of the Quality in Acute Stroke Care Protocol in Australia. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105931.	0.7	9
251	Productivity Benefits of Preventing Type 2 Diabetes in Australia: A 10-Year Analysis. Diabetes Care, 2021, 44, 715-721.	4.3	9
252	Cost-effectiveness of Crohn's disease post-operative care. World Journal of Gastroenterology, 2016, 22, 3860.	1.4	9

#	Article	IF	Citations
253	National nursing registration in Australia: A way forward for nurse practitioner endorsement. Journal of the American Academy of Nurse Practitioners, 2012, 24, 143-148.	1.4	8
254	Is It Costâ€Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort. Cardiovascular Therapeutics, 2013, 31, 45-52.	1.1	8
255	Outcomes and Excess Costs among Patients with Cardiovascular Disease. Heart Lung and Circulation, 2013, 22, 724-730.	0.2	8
256	An exploratory trial of insulin initiation and titration among patients with type 2 diabetes in the primary care setting with retrospective continuous glucose monitoring as an adjunct: INITIATION study protocol. BMC Family Practice, 2014, 15, 82.	2.9	8
257	GP-OSMOTIC trial protocol: an individually randomised controlled trial to determine the effect of retrospective continuous glucose monitoring (r-CGM) on HbA1c in adults with type 2 diabetes in general practice. BMJ Open, 2018, 8, e021435.	0.8	8
258	A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre. Value in Health, 2019, 22, 854-862.	0.1	8
259	Epidemiology of heart failure: Study of Heart failure in the Australian Primary carE setting (SHAPE). ESC Heart Failure, 2020, 7, 3871-3880.	1.4	8
260	Early signs that COVID-19 is being contained in Australia. Journal of Infection, 2020, 81, 318-356.	1.7	8
261	Cost-effectiveness of Radial Access Percutaneous Coronary Intervention in Acute Coronary Syndrome. American Journal of Cardiology, 2021, 156, 44-51.	0.7	8
262	Risk stratification for coronary artery disease in multi-ethnic populations: Are there broader considerations for cost efficiency?. World Journal of Methodology, 2019, 9, 1-19.	1.1	8
263	Estimating the economic impacts of percutaneous coronary intervention in Australia: a registry-based cost burden study. BMJ Open, 2021, 11, e053305.	0.8	8
264	The Cost of Control: Cost-effectiveness Analysis of Hybrid Closed-Loop Therapy in Youth. Diabetes Care, 2022, 45, 1971-1980.	4.3	8
265	Predicting the Effectiveness of Prevention: A Role for Epidemiological Modeling. Journal of Primary Prevention, 2008, 29, 295-305.	0.8	7
266	Predicting the Impact of Polypill Use in a Metabolic Syndrome Population: An Effectiveness and Cost-Effectiveness Analysis. American Journal of Cardiovascular Drugs, 2013, 13, 121-128.	1.0	7
267	The functions and roles of questioning during nursing handovers in specialty settings: an ethnographic study. Contemporary Nurse, 2017, 53, 182-195.	0.4	7
268	Is establishing a specialist back pain assessment and management service in primary care a safe and effective model? Twelve-month results from the Back pain Assessment Clinic (BAC) prospective cohort pilot study. BMJ Open, 2018, 8, e019275.	0.8	7
269	The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era. Inflammatory Bowel Diseases, 2020, 26, 369-379.	0.9	7
270	Predictors of statin use among older adults: A nationwide cross-sectional study. Journal of Clinical Lipidology, 2019, 13, 156-162.e1.	0.6	7

#	Article	IF	Citations
271	Outcomes of communityâ€based hepatitis C treatment by general practitioners and nurses in Australia through remote specialist consultation. Internal Medicine Journal, 2021, 51, 1927-1934.	0.5	7
272	A Scenario-Based Survey of Expert Echocardiography Recommendations for Patients With <i>Staphylococcus aureus </i> Bacteremia at Varying Risk for Endocarditis. JAMA Network Open, 2020, 3, e202401.	2.8	7
273	Sphingolipid imbalance and inflammatory effects induced by uremic toxins in heart and kidney cells are reversed by dihydroceramide desaturase 1 inhibition. Toxicology Letters, 2021, 350, 133-142.	0.4	7
274	Estimating the Productivity Burden of Pediatric Pneumococcal Disease in Thailand. Applied Health Economics and Health Policy, 2020, 18, 579-587.	1.0	7
275	Blood pressure and risk of breast cancer, overall and by subtypes. Journal of Hypertension, 2017, 35, 1371-1380.	0.3	7
276	Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study Journal of Clinical Oncology, 2017, 35, 1044-1044.	0.8	7
277	The effect of joint aspiration and corticosteroid injections in osteoarthritis of the knee. International Journal of Rheumatic Diseases, 2011, 14, 384-389.	0.9	6
278	Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry. Clinical Therapeutics, 2011, 33, 1456-1465.	1.1	6
279	Predictors of health care use among patients with or at high risk of atherothrombotic disease: Two-year follow-up data. International Journal of Cardiology, 2014, 175, 72-77.	0.8	6
280	Adverse Drug Reactions Associated With Cholinesterase Inhibitorsâ€"Sequence Symmetry Analyses Using Prescription Claims Data. Journal of the American Medical Directors Association, 2017, 18, 186-189.	1.2	6
281	Renal safety of shortâ€ŧerm empiric gentamicin therapy in aged patients. Australasian Journal on Ageing, 2018, 37, 227-231.	0.4	6
282	Clinical predictors and prediction rules to estimate initial patient risk for infective endocarditis in Staphylococcus aureus bacteraemia: attention must be paid to the reference standard. Clinical Microbiology and Infection, 2018, 24, 314-316.	2.8	6
283	Evaluating optimal utilisation of technology in type 1 diabetes mellitus from a clinical and health economic perspective: protocol for a systematic review. Systematic Reviews, 2018, 7, 44.	2.5	6
284	An epidemiological study of paediatric adenotonsillectomy in Victoria, Australia, 2010â€2015: Changing indications and lack of effect of hospital volume on interâ€hospital transfers. Clinical Otolaryngology, 2019, 44, 1037-1044.	0.6	6
285	Risk-Adjusting Key Outcome Measures in a Clinical Quality PCI Registry. JACC: Cardiovascular Interventions, 2019, 12, 1966-1975.	1.1	6
286	Ageâ€specific diastolic dysfunction improves prediction of symptomatic heart failure by Stage B heart failure. ESC Heart Failure, 2019, 6, 747-757.	1.4	6
287	Longâ€term persistence and adherence to blood pressure lowering agents among older Australians. Pharmacoepidemiology and Drug Safety, 2019, 28, 788-795.	0.9	6
288	Comparisons of direct and indirect utilities in adult epilepsy populations: A systematic review. Epilepsia, 2019, 60, 2466-2476.	2.6	6

#	Article	lF	Citations
289	An Economic Evaluation of the All New Zealand Acute Coronary Syndrome Quality Improvement Registry Program (ANZACS-QI 28). Heart Lung and Circulation, 2020, 29, 1046-1053.	0.2	6
290	The epidemiology of heart failure in the general Australian community - study of heart failure in the Australian primary carE setting (SHAPE): methods. BMC Public Health, 2020, 20, 648.	1.2	6
291	Effects of Statins for Secondary Prevention on Functioning and Other Outcomes Among Nursing Home Residents. Journal of the American Medical Directors Association, 2020, 21, 500-507.e8.	1.2	6
292	Frailty Confers High Mortality Risk across Different Populations: Evidence from an Overview of Systematic Reviews and Meta-Analyses. Geriatrics (Switzerland), 2020, 5, 17.	0.6	6
293	Recommended Intake of Key Food Groups and Cardiovascular Risk Factors in Australian Older, Rural-Dwelling Adults. Nutrients, 2020, 12, 860.	1.7	6
294	Cost-effectiveness of treatment of women aged 70Âyears and older with both osteopenia and microstructural deterioration. Bone, 2021, 142, 115682.	1.4	6
295	The Preventable Productivity Burden of Kidney Disease in Australia. Journal of the American Society of Nephrology: JASN, 2021, 32, 938-949.	3.0	6
296	Impact of emergency medical service delays on time to reperfusion and mortality in STEMI. Open Heart, 2021, 8, e001654.	0.9	6
297	Trends in the utilisation of lipid-lowering medications in Australia: an analysis of national pharmacy claims data. Current Problems in Cardiology, 2021, , 100880.	1.1	6
298	Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus. Endocrine Practice, 2022, 28, 16-24.	1.1	6
299	Assessing the impact of smoking on the health and productivity of the working-age Indonesian population using modelling. BMJ Open, 2020, 10, e041832.	0.8	6
300	The role of aldosterone receptor blockade in the management of cardiovascular disease. Current Opinion in Investigational Drugs, 2002, 3, 1468-73.	2.3	6
301	Outcomes of decompressive craniectomy in patients after traumatic brain injury. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2015, 17, 67-72.	0.0	6
302	The association between polypharmacy, frailty and disability-free survival in community-dwelling healthy older individuals. Archives of Gerontology and Geriatrics, 2022, 101, 104694.	1.4	6
303	Utility of B-Type Natriuretic Peptide as a Screen for Left Ventricular Dysfunction in Patients With Diabetes: Response to Epshteyn et al Diabetes Care, 2004, 27, 848-848.	4.3	5
304	Changes to the Statin Prescribing Policy in Belgium. American Journal of Cardiovascular Drugs, 2012, 12, 225-232.	1.0	5
305	Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia. Mycoses, 2012, 55, 244-256.	1.8	5
306	Health care costs associated with Australian tertiary inflammatory bowel disease care. Scandinavian Journal of Gastroenterology, 2017, 52, 851-856.	0.6	5

#	Article	IF	CITATIONS
307	Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia: the AusDiab study. European Journal of Clinical Pharmacology, 2018, 74, 1493-1501.	0.8	5
308	Communicating with patients, families and health professionals about managing medications in intensive care: A qualitative observational study. Intensive and Critical Care Nursing, 2019, 54, 15-22.	1.4	5
309	Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. Clinical Research in Cardiology, 2019, 108, 806-814.	1.5	5
310	Determining the cost of first-ever seizures: A narrative review and future directions. Epilepsy and Behavior, 2019, 90, 291-294.	0.9	5
311	Moderate or severe low back pain is associated with body mass index amongst community-dwelling older Australians. Archives of Gerontology and Geriatrics, 2020, 91, 104231.	1.4	5
312	Trends in the Dispensing and Costs of Glucose-Lowering Medications Among Older Australians: Findings from National Claims Data. Drugs and Aging, 2020, 37, 393-398.	1.3	5
313	Kidney age - chronological age difference (KCD) score provides an age-adapted measure of kidney function. BMC Nephrology, 2021, 22, 152.	0.8	5
314	Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis. PharmacoEconomics - Open, 2021, 5, 459-467.	0.9	5
315	Productivity burden of hypertension in Japan. Hypertension Research, 2021, 44, 1524-1533.	1.5	5
316	Gazing through time and beyond the health sector: Insights from a system dynamics model of cardiovascular disease in Australia. PLoS ONE, 2021, 16, e0257760.	1,1	5
317	Risk factors for asymptomatic echocardiographic abnormalities that predict symptomatic heart failure. ESC Heart Failure, 2021, , .	1.4	5
318	The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes. Nutrients, 2022, 14, 215.	1.7	5
319	Hospital revisits after paediatric tonsillectomy: a cohort study. Journal of Otolaryngology - Head and Neck Surgery, 2022, 51, 1.	0.9	5
320	A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. Current Problems in Cardiology, 2023, 48, 101211.	1.1	5
321	Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry. Cardiovascular Drugs and Therapy, 2018, 32, 57-64.	1.3	4
322	Clinical variation in the use of echocardiography in Staphylococcus aureus bacteraemia: a multi-centre cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 469-474.	1.3	4
323	Mind the Gap: Mismatches Between Clinicians and Patients in Heart Failure Medication Management. Cardiovascular Drugs and Therapy, 2018, 32, 37-46.	1.3	4
324	Dispensing Patterns of Blood Pressure Lowering Agents in Older Australians From 2006 to 2016. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 242-250.	1.0	4

#	Article	IF	CITATIONS
325	The Volunteer Dementia and Delirium Care (VDDC) \hat{A} © program: An exploration of perceived barriers and enablers to implementation in an acute and subacute metropolitan hospital. Australasian Journal on Ageing, 2020, 39, e334-e343.	0.4	4
326	Characterising experiences with acute myeloid leukaemia using an Instagram content analysis. PLoS ONE, 2021, 16, e0250641.	1.1	4
327	Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. BMJ Open, 2021, 11, e043921.	0.8	4
328	A Randomized Controlled Trial on the Effects of a 6-Month Home-Based Physical Activity Program with Individual Goal-Setting and Volunteer Mentors on Physical Activity, Adherence, and Physical Fitness in Inactive Older Adults at Risk of Cognitive Decline: The INDIGO Study. Journal of Alzheimer's Disease, 2021, 84, 207-226.	1.2	4
329	The effect of dihydroceramide desaturase 1 inhibition on endothelial impairment induced by indoxyl sulfate. Vascular Pharmacology, 2021, 141, 106923.	1.0	4
330	Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma P>. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 241-252.	0.7	4
331	Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review. JMIR Research Protocols, 2017, 6, e39.	0.5	4
332	The costâ€effectiveness of radial access percutaneous coronary intervention: A propensityâ€score matched analysis of Victorian data. Clinical Cardiology, 2022, 45, 435-446.	0.7	4
333	Estimating the benefits of obesity prevention on productivity: an Australian perspective. International Journal of Obesity, 2022, 46, 1463-1469.	1.6	4
334	Attainment of low-density lipoprotein cholesterol goals in patients treated with combination therapy: A retrospective cohort study in primary care. Journal of Clinical Lipidology, 2022, 16, 498-507.	0.6	4
335	A feeling in the waters: diagnosis of heart failure using urinary natriuretic peptides. Clinical Science, 2004, 106, 111-112.	1.8	3
336	The Impact of Lost Therapeutic Benefit (<scp>LTB</scp>) in Highâ€Risk Hypertensive Patients: 2â€Year Followâ€Up Data from the Australian <scp>REACH</scp> Registry. Cardiovascular Therapeutics, 2013, 31, 370-376.	1.1	3
337	Patterns of Medication Dispensation for Multiple Comorbidities among Older Adults in Australia. Pharmacy (Basel, Switzerland), 2018, 6, 134.	0.6	3
338	Early transthoracic echocardiography has useful prognostic value in left-sided native valve endocarditis despite limited diagnostic performance. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1569-1575.	1.3	3
339	Prescription of physical activity in the management of high blood pressure in Australian general practices. Journal of Human Hypertension, 2019, 33, 50-56.	1.0	3
340	The Volunteer Dementia and Delirium Care (VDDC)©: A preâ€implementation study exploring perceived acceptability to implementing the program in an acute and subacute metropolitan hospital. Australasian Journal on Ageing, 2020, 39, e322-e333.	0.4	3
341	Factors associated with improved walking in older people during hospital rehabilitation: secondary analysis of a randomized controlled trial. BMC Geriatrics, 2021, 21, 90.	1.1	3
342	Applying a framework to assess the impact of cardiovascular outcomes improvement research. Health Research Policy and Systems, 2021, 19, 67.	1.1	3

#	Article	IF	Citations
343	Potential positive effects of bariatric surgery on healthcare resource utilisation. ANZ Journal of Surgery, 2021, 91, 2436-2442.	0.3	3
344	Sex differences in Cardiac electronic device implantation: Outcomes from an Australian multi-centre clinical quality registry. IJC Heart and Vasculature, 2021, 35, 100828.	0.6	3
345	â€if I don't work, I don't get paid': An Australian qualitative exploration of the financial impacts of acute myeloid leukaemia. Health and Social Care in the Community, 2022, 30, .	0.7	3
346	Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 760-773.	0.2	3
347	Novel Biomedical Risk Markers for Cardiovascular Disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 41-55.	3.1	2
348	Eplerenone in the treatment of chronic heart failure. Expert Review of Cardiovascular Therapy, 2004, 2, 315-320.	0.6	2
349	A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatinâ€based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 172-179.	0.7	2
350	Does warfarin-related intracerebral haemorrhage lead to higher costs of management?. Clinical Neurology and Neurosurgery, 2014, 126, 38-42.	0.6	2
351	Neonatal vitamin D supplementation. Journal of Paediatrics and Child Health, 2017, 53, 725-726.	0.4	2
352	Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective. Applied Health Economics and Health Policy, 2017, 15, 363-374.	1.0	2
353	Effect of warfarin education on patient knowledge and anticoagulation control: a randomised controlled trial. Journal of Pharmacy Practice and Research, 2018, 48, 516-521.	0.5	2
354	Defining Optimal Care for Functional Gut Disorders - Multi-Disciplinary Versus Standard Care: A Randomized Controlled Trial Protocol. Contemporary Clinical Trials, 2019, 84, 105828.	0.8	2
355	Population Genomic Screening of All Young Adults in a Health-Care System: A Cost-Effectiveness Analysis. Obstetrical and Gynecological Survey, 2020, 75, 91-93.	0.2	2
356	Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price. Journal of Medical Economics, 2021, 24, 893-899.	1.0	2
357	Markers of Cardiovascular Disease among Adults Exposed to Smoke from the Hazelwood Coal Mine Fire. International Journal of Environmental Research and Public Health, 2021, 18, 1587.	1.2	2
358	Estimating the Productivity Impact of Acute Myeloid Leukemia in Australia Between 2020 and 2029, Using a Novel Work Utility Measure: The Productivity-Adjusted Life Year (PALY). JCO Oncology Practice, 2021, 17, e1803-e1810.	1.4	2
359	Characteristics and outcomes of unsuccessful percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, , .	0.7	2
360	Metal stents are safe and costâ€effective for preoperative biliary drainage in resectable pancreaticobiliary tumours. ANZ Journal of Surgery, 2021, 91, 1841-1846.	0.3	2

#	Article	IF	Citations
361	Sociodemographic associations of geographic variation in paediatric tonsillectomy and adenoidectomy. Scientific Reports, 2021, 11, 15896.	1.6	2
362	Relation of Timing of Percutaneous Coronary Intervention on Outcomes in Patients With Non-ST Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2020, 136, 15-23.	0.7	2
363	The Impact of Diabetes on Productivity in India. Diabetes Care, 2021, 44, 2714-2722.	4.3	2
364	Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system. Leukemia Research, 2022, 112, 106748.	0.4	2
365	Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia. Pharmacoeconomics, 2022, , 1.	1.7	2
366	Quality of life and associations with health-related behaviours among older adults with increased cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1146-1153.	1.1	2
367	Development and validation of a comprehensive early risk prediction model for patients with undifferentiated acute chest pain. IJC Heart and Vasculature, 2022, 40, 101043.	0.6	2
368	F1-01-03: THE INDIGO STUDY: A RANDOMIZED CONTROLLED TRIAL OF PHYSICAL ACTIVITY WITH INDIVIDUAL GOAL-SETTING AND VOLUNTEER MENTORS TO OVERCOME SEDENTARY LIFESTYLE IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE. , 2014, 10, P124-P124.		1
369	Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development. Future Cardiology, 2017, 13, 103-115.	0.5	1
370	Heterogeneity and Uncertainties Specific to Genome-Based Health Technological Assessments. Value in Health, 2018, 21, 891-893.	0.1	1
371	Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study. Diabetes Research and Clinical Practice, 2019, 158, 107909.	1.1	1
372	Aetiologies and factors associated with poor clinical outcomes in rhabdomyolysis: a retrospective cohort study in an Australian trauma centre. Internal Medicine Journal, 2021, 51, 264-267.	0.5	1
373	The Potential for Early Health Economic Modelling in Health Technology Assessment and Reimbursement DecisionMaking Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling". International Journal of Health Policy and Management, 2021, 10, 98-101.	0.5	1
374	Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan. Modern Rheumatology, 2023, 33, 54-63.	0.9	1
375	Prospective multisite cohort study of patientâ€reported outcomes in adults with newâ€onset seizures. Epilepsia Open, 2022, 7, 201-209.	1.3	1
376	Does Down syndrome influence the outcomes of congenital cardiac surgery? A systematic review and meta-analysis. European Heart Journal Quality of Care & Dutcomes, 2023, 9, 240-248.	1.8	1
377	The cardiovascular safety of celecoxib. Future Cardiology, 2005, 1, 709-722.	0.5	0
378	Hypolipidemic and antihypertensive drugs for prevention of cardiovascular complications in patients with rheumatoid arthritis. The Cochrane Library, 0 , , .	1.5	0

#	Article	IF	Citations
379	Reply. Journal of Hypertension, 2017, 35, 1722-1723.	0.3	O
380	Evaluation of the Effectiveness of a Phone Based Care Coordination Pilot on Hospital Utilisation and Costs for Patients With Chest Pain. Heart Lung and Circulation, 2018, 27, 147-153.	0.2	0
381	Temporal Changes in Characteristics, Treatment and Outcomes of Heart Failure Patients Undergoing Percutaneous Coronary Intervention Findings From Melbourne Interventional Group Registry. Heart Lung and Circulation, 2019, 28, 1018-1026.	0.2	0
382	Factors associated with hypertension and its management among older rural Australians. Australian Journal of Rural Health, 2020, 28, 399-407.	0.7	0
383	Evaluation of the Pain Impact Index for Communityâ€Dwelling Older Adults Through the Application of Rasch Modelling. Pain Practice, 2021, 21, 501-512.	0.9	0
384	Clinical Outcomes in Older Patients Undergoing Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndromes. Heart Lung and Circulation, 2021, 30, 275-281.	0.2	0
385	Costâ€analysis of opportunistic influenza vaccination in general medical inpatients. Internal Medicine Journal, 2021, 51, 591-595.	0.5	0
386	Redundancy in metaâ€analyses publications—Time to pull the plug. Journal of Thrombosis and Haemostasis, 2021, 19, 1589-1590.	1.9	0
387	IDDF2021-ABS-0126â€Exploring the gut microbiota variation in response to vibrio infection. , 2021, , .		0
388	It doesn't stop at validation: patient reported outcome measures require ongoing and iterative development. Supportive Care in Cancer, 2022, 30, 995-998.	1.0	0
389	Cost-Effectiveness of Non-Statin Lipid-Modifying Agents for Primary and Secondary Prevention of Cardiovascular Disease among Patients with Type 2 diabetes mellitus: A Systematic Review. Journal of Emergency Medicine, Trauma and Acute Care, 2022, 2022, .	0.1	0
390	Sex-Specific Outcomes Following Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Left Main Disease: A Systematic Review and Meta-Analysis. Heart Lung and Circulation, 2022, , .	0.2	0
391	Eplerenone. Pharmacia. Current Opinion in Investigational Drugs, 2003, 4, 316-22.	2.3	0
392	An economic evaluation of the All New Zealand Acute Coronary Syndrome Quality Improvement Registry programme-subanalyses for MÄori (ANZACS-QI 42). New Zealand Medical Journal, 2020, 133, 16-32.	0.5	0
393	Cost and economic determinants of paediatric tonsillectomy. Australian Health Review, 2022, 46, 153-162.	0.5	0
394	Vascular Responses Among Adults Four Years Post Exposure to 6 Weeks of Smoke from the Hazelwood Coal Mine Fire. Vascular Health and Risk Management, 2022, Volume 18, 253-265.	1.0	0
395	Impact of prehospital opioid dose on angiographic and clinical outcomes in acute coronary syndromes. Emergency Medicine Journal, 2022, , emermed-2021-211519.	0.4	0
396	Prior Coronary Artery Bypass Graft Surgery Impacts 30-day Quality of Life after Percutaneous Coronary Intervention: Evidence from the Victorian Cardiac Outcomes Registry (VCOR). Applied Research in Quality of Life, 0, , .	1.4	0